Alvotech (ALVO)vsHaleon plc (HLN)
ALVO
Alvotech
$3.54
-5.35%
HEALTHCARE · Cap: $1.05B
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $40.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1862% more annual revenue ($11.03B vs $562.04M). HLN leads profitability with a 15.1% profit margin vs -14.4%. HLN trades at a lower P/E of 18.2x. HLN earns a higher WallStSmart Score of 63/100 (C+).
ALVO
Avoid21
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.2%
Fair Value
$24.48
Current Price
$3.54
$20.94 discount
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ALVO
The strongest argument for ALVO centers on Debt/Equity.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : ALVO
The primary concerns for ALVO are P/E Ratio, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ALVO profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
HLN carries more volatility with a beta of 0.25 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 21/100), backed by strong 15.1% margins. ALVO offers better value entry with a 80.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alvotech
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?